SPRO
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Stock trades at a premium due to high growth expectations, but fundamentals do not support current price.
- P/E is lower than sector average
- Price exceeds Graham Number ($1.88)
- Price significantly exceeds Intrinsic Value ($1.05)
Growth metrics are the only bullish driver, though sustainability is questionable.
- Triple-digit Q/Q revenue growth
- Strong YoY revenue expansion
- Negative forward P/E
Recent momentum is strong, but long-term trend is destructive.
- Massive 1-year price appreciation (+264.7%)
- Poor 5-year performance (-77.5%)
High liquidity masks poor fundamental health trends.
- Low Debt/Equity
- High Current Ratio
- Piotroski F-Score of 2/9 indicates weak operational health
Typical for biotech growth stage.
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SPRO and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SPRO
Spero Therapeutics, Inc.
Primary
|
-77.5% | +57.1% | +264.7% | +24.4% | +11.8% | +3.0% |
|
HRTX
Heron Therapeutics, Inc.
Peer
|
-94.8% | -68.8% | -53.1% | -33.4% | -12.1% | +6.6% |
|
RCEL
AVITA Medical, Inc.
Peer
|
-74.5% | -65.7% | -44.2% | +28.8% | +22.7% | +2.6% |
|
QIPT
Quipt Home Medical Corp
Peer
|
-44.7% | -42.7% | +56.0% | +34.2% | +1.1% | 0.0% |
|
ACH
Accendra Health, Inc.
Peer
|
-92.8% | -89.2% | -85.8% | -73.2% | -22.1% | -16.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SPRO
Spero Therapeutics, Inc.
|
BEARISH | $159.2M | 18.33 | 16.3% | 12.8% | $2.75 | |
|
HRTX
Heron Therapeutics, Inc.
|
BEARISH | $160.82M | - | -% | -13.0% | $0.85 | Compare |
|
RCEL
AVITA Medical, Inc.
|
BEARISH | $157.45M | - | -% | -67.8% | $5.14 | Compare |
|
QIPT
Quipt Home Medical Corp
|
BEARISH | $162.3M | - | -9.3% | -4.0% | $3.65 | Compare |
|
ACH
Accendra Health, Inc.
|
BEARISH | $163.2M | - | -196.4% | -12.4% | $2.11 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-06 | KEUTZER TIMOTHY | Chief Operating Officer | Sale | 18,652 | $44,019 |
| 2026-02-06 | RAJAVELU ESTHER | Chief Executive Officer | Sale | 87,917 | $207,484 |
| 2026-02-04 | KEUTZER TIMOTHY | Chief Operating Officer | Sale | 46,586 | $101,175 |
| 2026-02-02 | KEUTZER TIMOTHY | Chief Operating Officer | Stock Award | 68,000 | - |
| 2026-02-02 | RAJAVELU ESTHER | Chief Executive Officer | Stock Award | 249,000 | - |
| 2026-02-02 | RAJAVELU ESTHER | Chief Executive Officer | Sale | 18,442 | $40,572 |
| 2025-11-07 | RAJAVELU ESTHER | Chief Executive Officer | Sale | 40,270 | $95,440 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Past News Coverage
Recent headlines mentioning SPRO from our newsroom.